Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
Coronavirus COVID-19 South Korea Approvals

Celltrion Antibody Becomes First Home-Grown COVID-19 Drug Approval In Korea

  • Analysis

Executive Summary

Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.

You may also be interested in...



Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic. 

Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy

In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.

Celltrion Accelerates Antibody, Kit Development As It Takes Coronavirus Initiative

Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 South Korea Approvals
UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By